Abstract:INTRODUCTION AND OBJECTIVE: Regulatory T cells (Tregs) play a major role in the development of an immunosuppressive tumor microenvironment. CCR8 has recently been identified as an important chemokine receptor on intratumoral Tregs and is known to be critical for CCR8+Treg-mediated immunosuppression. This study aimed to investigate the clinical significance and inherent molecular mechanisms of intratumoral CCR8+ Tregs in Muscle-invasive bladder cancer (MIBC). METHODS: 259 MIBC patients from two independent clinic centers were included in the study. 83 fresh MIBC tumor tissues were used to evaluate the proportion and function of immune cells via flow cytometry and ex vivo intervention experiments. 396 MIBC patients of TCGA were applied for bioinformatics analysis. RESULTS: We found that the CCR8 expression by intratumoral Tregs maintained the stability and potentiated their suppressive function by upregulating the expression of transcript factors Foxo1 and c-Maf. High level of CCR8+ Tregs is associated with immune tolerance and predicts poor survival and inferior therapeutic responsiveness to chemotherapy. Moreover, we revealed that CCR8 blockade using neutralizing antibody destabilized intratumoral Tregs into a fragile phenotype, reactivated the antitumor immunity and augmented the therapeutic benefits of the anti-PD-1 antibody in MIBC. CONCLUSIONS: Our study presents the mechanism of CCR8 in maintaining the stability of intratumoral Tregs in MIBC and indicates that therapeutic targeting of CCR8 could provide a more specific modulation of Tregs and augment immunotherapy in patients with MIBC.Source of Funding: This study was funded by grants from National Natural Science Foundation of China (81570607, 81671628, 31770851, 81702496, 81702497, 81702805, 81772696, 81871306, 81872082, 81902556, 81902563, 81902898, 81974393), Three-year action plan for promoting clinical skills and clinical innovation in municipal hospitals of Shanghai Shenkang (16CR2003A), National Natural Science Foundation for Young Scholars of China (81902566), Shanghai Jiaotong University Medical-Engineering Cross Research Fund (YG2019QNA53), National Key R&D Program of China (2017YFC0114303), Shanghai Municipal Natural Science Foundation (16ZR1406500, 17ZR1405100, 19ZR1431800), Guide Project of Science and Technology Commission of Shanghai Municipality (17411963100), Shanghai Sailing Program (18YF1404500, 19YF1407900, 19YF1427200), Shanghai Municipal Commission of Health and Family Planning Program (20174Y0042, 201840168, 20184Y0151), Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation (YJYQ201802) and Shanghai Cancer Research Charity Center. All these study sponsors have no roles in the study design, in the collection, analysis and interpretation of data.

Identification and Validation of an Excellent Prognosis Subtype of Muscle-Invasive Bladder Cancer Patients with Intratumoral CXCR5+ CD8+ T Cell Abundance.

Identification of a Cisplatin Resistant-Based Prognostic Immune Related Gene Signature in MIBC

Intratumoral CCR5+ neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses

Intratumoral TIGIT + CD8 + T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer

CD19(+) Tumor-Infiltrating B-cells Prime CD4(+) T-cell Immunity and Predict Platinum-Based Chemotherapy Efficacy in Muscle-Invasive Bladder Cancer

CXCR6 Expression Predicts Prognosis and Immunotherapeutic Benefit in Muscle-Invasive Bladder Cancer

Single-cell Sequencing Data Reveals Aggressive CD68-type Macrophages and Prognostic Models in Bladder Cancer.

Intratumoral IL22-producing Cells Define Immunoevasive Subtype Muscle-Invasive Bladder Cancer with Poor Prognosis and Superior Nivolumab Responses

CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer

Stromal LAG-3+cells Infiltration Defines Poor Prognosis Subtype Muscle-Invasive Bladder Cancer with Immunoevasive Contexture

Identification and Validation of Poor Prognosis Immunoevasive Subtype of Muscle-Invasive Bladder Cancer with Tumor-Infiltrating Podoplanin+ Cell Abundance.

Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma

Tumor-infiltrating IL-17A+ Cells Determine Favorable Prognosis and Adjuvant Chemotherapeutic Response in Muscle-Invasive Bladder Cancer

CD103+ Tissue-Resident CD8+ T Cells Correlate with Protective Anti-Tumoral Immune Responses in Muscle-Invasive Bladder Cancer Patients.

A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer.

TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer

Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer

Mp55-02 ccr8 blockade primes anti-tumor immunity through intratumoral regulatory t cells destabilization in muscle-invasive bladder cancer

Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer

Poor Clinical Outcomes and Immunoevasive Contexture in Interleukin‐9 Abundant Muscle‐invasive Bladder Cancer